<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cystic <z:mp ids='MP_0003045'>fibrosis</z:mp> <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver disease</z:e> (CFLD) is a <z:hpo ids='HP_0003678'>rapidly progressive</z:hpo> biliary <z:mp ids='MP_0003045'>fibrosis</z:mp>, resembling primary sclerosing <z:mp ids='MP_0003254'>cholangitis</z:mp> that develops in 5-10% of patients with cystic <z:mp ids='MP_0003045'>fibrosis</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Further research and evaluation of therapies are hampered by the lack of a mouse model for CFLD </plain></SENT>
<SENT sid="2" pm="."><plain>Although primary sclerosing <z:mp ids='MP_0003254'>cholangitis</z:mp> is linked to both <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> and loss of cystic <z:mp ids='MP_0003045'>fibrosis</z:mp> transmembrane conductance regulator (CFTR) ion channel function, induction of <z:hpo ids='HP_0002583'>colitis</z:hpo> with <z:chebi fb="0" ids="52071">dextran</z:chebi> <z:chebi fb="0" ids="32149">sodium sulfate</z:chebi> (DSS) in cftr(-/-) mice causes bile duct injury but no <z:mp ids='MP_0003045'>fibrosis</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Since profibrogenic modifier genes are linked to CFLD, we examined whether subthreshhold doses of the profibrogenic <z:chebi fb="0" ids="35703">xenobiotic</z:chebi> 3,5-diethoxycarbonyl-1,4-dihydrocollidine (<z:chebi fb="5" ids="10101">DDC</z:chebi>), along with DSS-induced <z:hpo ids='HP_0002583'>colitis</z:hpo>, lead to bile duct injury and <z:mp ids='MP_0003333'>liver fibrosis</z:mp> in mice that harbor loss of CFTR function </plain></SENT>
<SENT sid="4" pm="."><plain>Exon 10 heterozygous (cftr(+/-)) and homozygous (cftr(-/-)) mice treated with <z:chebi fb="5" ids="10101">DDC</z:chebi> demonstrated extensive mononuclear cell <z:mp ids='MP_0001845'>inflammation</z:mp>, <z:hpo ids='HP_0001408'>bile duct proliferation</z:hpo>, and periductular <z:mp ids='MP_0003045'>fibrosis</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, <z:mp ids='MP_0002169'>wild-type</z:mp> (cftr(+/+)) littermates did not develop bile duct injury or <z:mp ids='MP_0003045'>fibrosis</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>Histological changes corresponded to increased levels of alkaline phosphatase, <z:chebi fb="2" ids="18095">hydroxyproline</z:chebi>, and expression of profibrogenic transcripts for transforming growth factor-β(1), transforming growth factor-β(2), procollagen α(1)(I), and tissue inhibitor of matrix metaloproteinase-1 </plain></SENT>
<SENT sid="7" pm="."><plain>Immunohistochemistry demonstrated <z:mp ids='MP_0003045'>fibrosis</z:mp> and activation of periductal fibrogenic cells based on positive staining for <z:chebi fb="0" ids="32568">lysyl</z:chebi> oxidase-like-2, α-smooth muscle actin, and collagen I </plain></SENT>
<SENT sid="8" pm="."><plain>These data demonstrate that subthreshold doses of <z:chebi fb="5" ids="10101">DDC</z:chebi>, in conjunction with DSS-induced <z:hpo ids='HP_0002583'>colitis</z:hpo>, results in bile duct injury and periductal <z:mp ids='MP_0003045'>fibrosis</z:mp> in mice with partial or complete loss of CFTR function and may represent a useful model to study the pathogenic mechanisms by which CFTR dysfunction predisposes to fibrotic <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver disease</z:e> and potential therapies </plain></SENT>
</text></document>